If you can become pregnant, it’s important to consider whether Gvoke is a safe choice for you. It’s not known whether Gvoke is safe to use during pregnancy. This drug hasn’t been studied extensively ...

Xeris Pharmaceuticals, a specialty pharmaceutical company, is introducing Gvoke HypoPen (glucagon injection) for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

Approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen at launch Easy to use: premixed and ready-to-go A reliable method of delivery: 99% of people were ...

Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic patients ...

Gvoke (glucagon) can cause side effects that range from mild to serious. More common side effects include nausea and vomiting. If side effects from Gvoke become difficult to tolerate, talk with your ...

First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch ...

The new Gvoke Kit formulation is available as a 1mg/0.2mL single-dose vial and syringe kit. Gvoke ® Kit is now available for the treatment of severe hypoglycemia in adult and pediatric patients with ...

Gvoke VialDx is expected to be available in the third quarter of 2025. The Food and Drug Administration (FDA) has approved Gvoke VialDx ™ (glucagon) for intravenous use as a diagnostic aid during ...